Yaron Werber
Stock Analyst at TD Cowen
(1.99)
# 2,898
Out of 4,711 analysts
46
Total ratings
43.75%
Success rate
-9.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Initiates: Buy | n/a | $23.80 | - | 1 | Dec 20, 2024 | |
| SEPN Septerna | Initiates: Buy | n/a | $24.28 | - | 1 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $160 → $153 | $136.38 | +12.19% | 5 | Nov 15, 2024 | |
| BGNE BeiGene | Maintains: Buy | $254 → $260 | $176.50 | +47.31% | 6 | Nov 13, 2024 | |
| BNTX BioNTech SE | Maintains: Hold | $132 → $122 | $113.08 | +7.89% | 5 | Nov 6, 2024 | |
| UPB Upstream Bio | Initiates: Buy | n/a | $16.21 | - | 1 | Nov 5, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $61 → $73 | $44.22 | +65.08% | 2 | Oct 21, 2024 | |
| EXEL Exelixis | Maintains: Buy | $27 → $34 | $33.29 | +2.13% | 2 | Oct 21, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $54 → $59 | $35.63 | +65.59% | 1 | Jul 23, 2024 | |
| LEGN Legend Biotech | Maintains: Buy | $71 → $67 | $34.08 | +96.60% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $11.68 | - | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $21.57 | - | 1 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.00 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.14 | - | 2 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $25.14 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $612 → $641 | $623.82 | +2.75% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.19 | - | 1 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $25 | $0.40 | +6,150.00% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $20.61 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $20.31 | +87.10% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.50 | - | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.77 | - | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.57 | - | 1 | Oct 26, 2021 |
Dianthus Therapeutics
Dec 20, 2024
Initiates: Buy
Price Target: n/a
Current: $23.80
Upside: -
Septerna
Nov 19, 2024
Initiates: Buy
Price Target: n/a
Current: $24.28
Upside: -
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $160 → $153
Current: $136.38
Upside: +12.19%
BeiGene
Nov 13, 2024
Maintains: Buy
Price Target: $254 → $260
Current: $176.50
Upside: +47.31%
BioNTech SE
Nov 6, 2024
Maintains: Hold
Price Target: $132 → $122
Current: $113.08
Upside: +7.89%
Upstream Bio
Nov 5, 2024
Initiates: Buy
Price Target: n/a
Current: $16.21
Upside: -
Ultragenyx Pharmaceutical
Oct 21, 2024
Maintains: Buy
Price Target: $61 → $73
Current: $44.22
Upside: +65.08%
Exelixis
Oct 21, 2024
Maintains: Buy
Price Target: $27 → $34
Current: $33.29
Upside: +2.13%
Ionis Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $54 → $59
Current: $35.63
Upside: +65.59%
Legend Biotech
Jul 15, 2024
Maintains: Buy
Price Target: $71 → $67
Current: $34.08
Upside: +96.60%
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $11.68
Upside: -
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $21.57
Upside: -
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.00
Upside: -
Jan 31, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.14
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $25.14
Upside: -
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $623.82
Upside: +2.75%
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.19
Upside: -
Feb 28, 2023
Maintains: Market Perform
Price Target: $15 → $25
Current: $0.40
Upside: +6,150.00%
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $20.61
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $20.31
Upside: +87.10%
Apr 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $8.50
Upside: -
Nov 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.77
Upside: -
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.57
Upside: -